FINANCIAL STATEMENTS 134 ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2007 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 10 INTANGIBLE ASSETS CONTINUED Significant assets Carrying Remaining value amortisation Description $m period 1 Intangible assets arising from joint venture with Merck Product, marketing and distribution rights 298 6 and 10 years 1 Advance payment Product, marketing and distribution rights 704 11 years 2 Intangible assets arising from the acquisition of CAT Product, marketing and distribution rights 585 8 and 13 years 2 Intangible assets arising from the acquisition of KuDOS Product, marketing and distribution rights 285 Not amortised Intangible assets arising from the acquisition of MedImmune Product, marketing and distribution rights 5,916 18-24 years Intangible assets arising from the acquisition of MedImmune Licensing and contractual income 1,314 2-13 years 2 Intangible assets arising from the acquisition of MedImmune Product, marketing and distribution rights 576 Not amortised 1 These assets are associated with the restructuring of the joint venture with Merck & Co. Inc. Further information can be found in Note 27.
2 Assets in development are not amortised but are tested annually for impairment.
11 OTHER INVESTMENTS 2007 2006 2005 $m $m $m Non-current investments Loans and receivables at fair value through profit or loss 37 100 Equity securities available for sale 182 82 156 182 119 256 Current investments Equity securities held for trading 31 26 16 Fixed deposits 60 559 1,549 Derivative financial instruments 86 72 59 177 657 1,624 Impairment charges of $18m in respect of available for sale securities are included in other operating income and expense in the income statement 2006 $nil, 2005 $16m included in research and development.
In 2006, the Group completed the acquisition of Cambridge Antibody Technology Group plc, which was previously held as an available for sale investment.
12 INVENTORIES 2007 2006 2005 $m $m $m Raw materials and consumables 579 541 491 Inventories in process 806 778 957 Finished goods and goods for re-sale 734 931 758 2,119 2,250 2,206 Inventory write-offs in the year amounted to $95m 2006 $137m, 2005 $147m.
